Sikora Marta, Bretes Ewa, Perła-Kaján Joanna, Lewandowska Izabela, Marczak Łukasz, Jakubowski Hieronim
European Centre for Bioinformatics and Genomics, Institute of Bioorganic Chemistry, 61-704 Poznań, Poland.
Department of Biochemistry and Biotechnology, Poznań University of Life Sciences, 60-632 Poznań, Poland.
Antioxidants (Basel). 2020 Nov 28;9(12):1198. doi: 10.3390/antiox9121198.
High-density lipoprotein (HDL), in addition to promoting reverse cholesterol transport, possesses anti-inflammatory, antioxidative, and antithrombotic activities. Paraoxonase 1 (PON1), carried on HDL in the blood, can contribute to these antiatherogenic activities. The - polymorphism involves a change from glutamine (Q variant) to arginine (R variant) at position 192 of the PON1 protein and affects its enzymatic activity. The molecular basis of PON1 association with cardiovascular and neurological diseases is not fully understood. To get insight into the function of PON1 in human disease, we examined how genetic attenuation of PON1 levels/activity affect plasma proteomes of mice and humans. Healthy participants (48.9 years old, 50% women) were randomly recruited from the Poznań population. Four-month-old ( = 17) and ( = 8) mice (50% female) were used in these experiments. Plasma proteomes were analyzed using label-free mass spectrometry. Bioinformatics analysis was carried out using the Ingenuity Pathway Analysis (IPA) resources. polymorphism and genotype induced similar changes in plasma proteomes of humans and mice, respectively. The top molecular network, identified by IPA, affected by these changes involved proteins participating in lipoprotein metabolism. Other genotype-dependent proteomic changes affect different biological networks in humans and mice: "cardiovascular, neurological disease, organismal injury/abnormalities" in humans and "humoral immune response, inflammatory response, protein synthesis" and "cell-to-cell signaling/interaction, hematological system development/function, immune cell trafficking" in mice. Our findings suggest that PON1 interacts with molecular pathways involved in lipoprotein metabolism, acute/inflammatory response, and complement/blood coagulation that are essential for blood homeostasis. Modulation of those interactions by the genotype can account for its association with cardiovascular and neurological diseases.
高密度脂蛋白(HDL)除了促进胆固醇逆向转运外,还具有抗炎、抗氧化和抗血栓形成活性。血液中HDL携带的对氧磷酶1(PON1)有助于这些抗动脉粥样硬化活性。PON1基因多态性涉及PON1蛋白第192位的谷氨酰胺(Q变体)变为精氨酸(R变体),并影响其酶活性。PON1与心血管疾病和神经疾病关联的分子基础尚未完全明确。为深入了解PON1在人类疾病中的功能,我们研究了PON1水平/活性的基因衰减如何影响小鼠和人类的血浆蛋白质组。健康参与者(48.9岁,50%为女性)从波兹南人群中随机招募。在这些实验中使用了4个月大的(n = 17)和(n = 8)小鼠(50%为雌性)。使用无标记质谱分析血浆蛋白质组。使用 Ingenuity Pathway Analysis(IPA)资源进行生物信息学分析。PON1基因多态性和基因型分别在人类和小鼠的血浆蛋白质组中引起了相似的变化。IPA识别出的受这些变化影响的顶级分子网络涉及参与脂蛋白代谢的蛋白质。其他基因型依赖性蛋白质组变化在人类和小鼠中影响不同的生物网络:在人类中为“心血管、神经疾病、机体损伤/异常”,在小鼠中为“体液免疫反应、炎症反应、蛋白质合成”以及“细胞间信号传导/相互作用、血液系统发育/功能、免疫细胞运输”。我们的研究结果表明,PON1与参与脂蛋白代谢、急性/炎症反应以及对血液稳态至关重要的补体/血液凝固的分子途径相互作用。基因型对这些相互作用的调节可以解释其与心血管疾病和神经疾病的关联。